3.99
+0.44(+12.39%)
Currency In USD
| Previous Close | 3.55 |
| Open | 3.53 |
| Day High | 4.04 |
| Day Low | 3.53 |
| 52-Week High | 4.66 |
| 52-Week Low | 1.42 |
| Volume | 1.83M |
| Average Volume | 1.22M |
| Market Cap | 334.93M |
| PE | -4.24 |
| EPS | -0.94 |
| Moving Average 50 Days | 3.65 |
| Moving Average 200 Days | 2.63 |
| Change | 0.44 |
aTyr Pharma Announces Publication Demonstrating Efzofitimod’s Immunomodulatory Activity in Science Translational Medicine
GlobeNewswire Inc.
Yesterday at 8:00 PM GMT
Peer-reviewed publication validates efzofitimod’s unique anti-inflammatory mechanism of action on macrophages through neuropilin-2 (NRP2) receptor. Scientific insights further strengthen the rationale for clinical program for efzofitimod in interstit
aTyr Pharma Announces Fourth Positive DSMB Review for Efzofitimod in Phase 3 EFZO-FIT™ Study in Pulmonary Sarcoidosis
GlobeNewswire Inc.
Mar 06, 2025 9:02 PM GMT
No safety concerns identified by independent data and safety monitoring board (DSMB), which recommends continuation of study without any modifications.SAN DIEGO, March 06, 2025 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR) (“aTyr” or the “Co
aTyr Pharma to Webcast Conference Call Reporting Fourth Quarter and Full Year End 2024 Financial Results
GlobeNewswire Inc.
Mar 04, 2025 1:00 PM GMT
Management to host conference call and webcast on March 13th at 5:00 pm EDT / 2:00 pm PDTSAN DIEGO, March 04, 2025 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR), a clinical stage biotechnology company engaged in the discovery and development